RAC1 signaling in polyploid giant cancer cells: Implications for tumorigenesis and therapy resistance
Cancer Letters · 2026-09 · 656 · 218619
DOI: 10.1016/j.canlet.2026.218619 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-09. Verfasst von Lakshmi Kavitha Sthanam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: rac1 GTP-Binding Protein, Drug Resistance, Neoplasm, Polyploidy, Carcinogenesis. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Polyploid giant cancer cells (PGCCs) are a subpopulation of tumor cells known for driving tumor recurrence, metastasis, and therapeutic resistance. PGCCs arise mainly in response to cellular stress induced by cancer therapies and adverse microenvironmental conditions. We have recently demonstrated that a RAC1 mutation (RAC1 P34R) can induce the formation of PGCCs in aggressive thyroid cancer cells from a patient undergoing dabrafenib treatment, leading to resistance to therapy. RAC1 is a critical regulator and integrator molecule that mediates multiple cellular processes ranging from stress adaptation, metabolic regulation, cytoskeletal dynamics, motility, and cytokinesis. Importantly, RAC1’s functions are highly context-dependent, varying across a cell’s life cycle stages in response to dynamic biomechanical factors from the tumor microenvironment. This complexity underscores the need for precision targeting strategies that account for RAC1’s dynamic roles. Therapeutic approaches aimed at modulating RAC1 must be tailored to the specific cellular context and PGCC state to effectively disrupt the mechanisms underlying tumor progression. By targeting RAC1’s integrative functions, researchers may unlock new avenues for preventing PGCC-mediated recurrence and metastasis, offering a promising strategy to improve long-term outcomes in cancer treatment. This review outlines the diverse functions of RAC1 that may contribute to both the formation and sustained maintenance of PGCCs across various tumor types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mhofmann@mdanderson.org.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- University of Texas MD Anderson Cancer Center
- National Institutes of Health
Zitieren
APA
Sthanam, L. K., Mendez, P. M., McBeath, E., Cruz, L., Bagheri-Yarmand, R., & Hofmann, M. C. (2026). RAC1 signaling in polyploid giant cancer cells: Implications for tumorigenesis and therapy resistance. Cancer Letters, 656, 218619. https://doi.org/10.1016/j.canlet.2026.218619
Vancouver
Sthanam LK, Mendez PM, McBeath E, Cruz L, Bagheri-Yarmand R, Hofmann MC. RAC1 signaling in polyploid giant cancer cells: Implications for tumorigenesis and therapy resistance. Cancer Letters. 2026;656:218619. doi:10.1016/j.canlet.2026.218619
BibTeX
@article{Sthanam2026,
author = {Sthanam, Lakshmi Kavitha and Mendez, Paola Miranda and McBeath, Elena and Cruz, Leonardo and Bagheri-Yarmand, Rozita and Hofmann, Marie-Claude},
title = {RAC1 signaling in polyploid giant cancer cells: Implications for tumorigenesis and therapy resistance},
journal = {Cancer Letters},
year = {2026},
volume = {656},
pages = {218619},
doi = {10.1016/j.canlet.2026.218619}
}
EUVIMED